SCM
MDNA

Silverarc Capital Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Silverarc Capital Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-110,515
Closed -$333 – 110
2021
Q2 		$333 Buy
110,515
+2,979
+3% +$11K 0.15% 87
2021
Q1 		$439K Hold
107,536
– – 0.24% 77
2020
Q4 		$503K Buy
+107,536
New +$433K 0.29% 73

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Silverarc Capital Management's MDNA Position: Q3 2021 in Review

Silverarc Capital Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2021, closing a stake of 110,515 shares — an estimated $333 sold.

Silverarc Capital Management first reported a position in MDNA in Q4 2020 and held it in 3 quarters. The position peaked at $503K in Q4 2020. 25 funds tracked by Wall St. Rank hold MDNA as of Q3 2021.

  • Silverarc Capital Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 110,515 Medicenna Therapeutics Corp. Common Shares shares in Q3 2021, an estimated $333.
  • Silverarc Capital Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q4 2020 and held it in 3 quarters.
  • Silverarc Capital Management's Medicenna Therapeutics Corp. Common Shares position peaked at $503K in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.